What is FBLG's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for FBLG?

P/E (TTM) is n/a and 52-week range is $0.62 to $10.33 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s FBLG figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for FBLG?

The company profile lists net income (TTM) near $-35M, EPS (TTM) near $-5.74 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Fibrobiologics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Houston, Texas, US, 6.1M shares outstanding, ISIN US31573L2043 when available from company profile and filing metadata.

Fibrobiologics Inc

$FBLG

Health Care · Biotechnology

IR Run Scenarios

$1.13

+1.80%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 15 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

Employees

Website

fibrobiologics.com/

IPO

2024-01-31

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)